Advances in Risk-Stratification and Therapeutic Options for Early-Stage Non–Small Cell Lung Cancer


This publication reviews the role of adjuvant therapy with targeted agents, particularly with third-generation epidermal growth factor receptor tyrosine kinase inhibitors, for the treatment of non–small-cell lung cancer, recapping key insights from a scientific interchange & workshop.

Related Videos
Corey J. Langer, MD
John F. Lazar, MD
Rodolfo Bordoni, MD
Related Content